Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.55 |
| ▸ | NOS1 | P29475 | 2/20 | 0.55 |
| ▸ | NOS2 | P35228 | 2/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.40 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.38 |
| ▸ | GSR | P00390 | 2/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | GRM8 | O00222 | 1/20 | 0.38 |
| ▸ | GRM6 | O15303 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8093094 | 1.00 | NOS3 (0.55) | NOS3NOS1NOS2PTGS1SLC7A11 | |
| SCHEMBL617875 | 1.00 | NOS3 (0.55) | NOS3NOS1NOS2PTGS1SLC7A11 | |
| SCHEMBL890468 | 0.96 | NOS3 (0.51) | NOS3NOS1NOS2PTGS1SLC7A11 | |
| SCHEMBL890472 | 0.96 | NOS3 (0.51) | NOS3NOS1NOS2PTGS1SLC7A11 | |
| SCHEMBL22091990 | 0.87 | NOS3 (0.51) | NOS3NOS1NOS2PTGS1SLC7A11 | |
| SCHEMBL22091993 | 0.87 | NOS3 (0.51) | NOS3NOS1NOS2PTGS1SLC7A11 | |
| SCHEMBL31688563 | 0.84 | NOS3 (0.53) | NOS3NOS1NOS2PTGS1SLC7A11 | |
| SCHEMBL17434420 | 0.83 | NOS3 (0.53) | NOS3NOS1NOS2PTGS1SLC7A11 | |
| SCHEMBL9423322 | 0.83 | NOS3 (0.53) | NOS3NOS1NOS2PTGS1SLC7A11 | |
| SCHEMBL8892097 | 0.83 | NOS3 (0.53) | NOS3NOS1NOS2PTGS1SLC7A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100513386-C | Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils | DOMP S P A (IT) | 2009-07-15 | — | — | CN | claimed |
| CN-1205220-C | Novel cyclosporins | CHEM AG C (CH) | 2005-06-08 | — | — | CN | claimed |
| CN-1479715-A | Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils | ��ķ�ɷ�����˾ | 2004-03-03 | — | — | CN | claimed |
| CN-1305493-A | Novel cyclosporins | CHEM AG C (CH) | 2001-07-25 | — | — | CN | claimed |
| US-20250250565-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2025-08-07 | — | — | US | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-118184532-A | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-113454058-B | Amino acid having functional group capable of forming intramolecular hydrogen bond, peptide compound containing the amino acid, and process for producing the same | 中外制药株式会社 | 2024-03-22 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20240002853-A1 | NUCLEIC ACID DUPLEXES | ALPHA ANOMERIC SAS (FR) | 2024-01-04 | — | — | US | disclosed |
| US-11807664-B2 | Method for producing cyclic organic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-07 | — | — | US | disclosed |
| US-11807664-B2 | Method for producing cyclic organic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-07 | — | — | US | disclosed |
| WO-2019215333-A1 | OLIGONUCLEOTIDES CONJUGATES COMPRISING 7'-5'-ALPHA-ANOMERIC-BICYCLIC SUGAR NUCLEOSIDES | ALPHA ANOMERIC SAS (FR) | 2019-11-14 | — | — | WO | disclosed |
| CN-100513386-C | Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils | DOMP S P A (IT) | 2009-07-15 | — | — | CN | disclosed |
| CN-1205220-C | Novel cyclosporins | CHEM AG C (CH) | 2005-06-08 | — | — | CN | disclosed |
| EP-1282722-A4 | STABILIZED PROTEINS | AVATAR MEDICAL L L C (US) | 2004-04-07 | — | — | EP | disclosed |
| CN-1479715-A | Amides for inhibiting interleukin 8-induced chemotaxis of neutrophils | ��ķ�ɷ�����˾ | 2004-03-03 | — | — | CN | disclosed |
| EP-1282722-A1 | STABILIZED PROTEINS | Avatar Medical, L.L.C. (US) | 2003-02-12 | — | — | EP | disclosed |
| CN-1305493-A | Novel cyclosporins | CHEM AG C (CH) | 2001-07-25 | — | — | CN | disclosed |
| WO-2001029247-A1 | STABILIZED PROTEINS | AVATAR MEDICAL, LLC (US) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002853-A1 | NUCLEIC ACID DUPLEXES | NOP2, NOP58, POLRMT | NOS3 3715/4885NOS1 3230/4885NOS2 3650/4885 |
| US-11807664-B2 | Method for producing cyclic organic compound | SCTR, CTRC, DCXR | NOS3 282/4885NOS1 267/4885NOS2 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.